Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mou… Read more
Staidson Beijing Biopharma (300204) - Total Assets
Latest total assets as of September 2025: CN¥1.26 Billion CNY
Based on the latest financial reports, Staidson Beijing Biopharma (300204) holds total assets worth CN¥1.26 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Staidson Beijing Biopharma - Total Assets Trend (2007–2024)
This chart illustrates how Staidson Beijing Biopharma’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Staidson Beijing Biopharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Staidson Beijing Biopharma's total assets of CN¥1.26 Billion consist of 15.5% current assets and 84.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.7% |
| Accounts Receivable | CN¥39.72 Million | 3.5% |
| Inventory | CN¥22.18 Million | 1.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥152.34 Million | 13.3% |
| Goodwill | CN¥19.75 Million | 1.7% |
Asset Composition Trend (2007–2024)
This chart illustrates how Staidson Beijing Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Staidson Beijing Biopharma's current assets represent 15.5% of total assets in 2024, a decrease from 46.7% in 2007.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2024, down from 16.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 24.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 13.3% of total assets.
Staidson Beijing Biopharma Competitors by Total Assets
Key competitors of Staidson Beijing Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Staidson Beijing Biopharma - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Staidson Beijing Biopharma generates 0.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Staidson Beijing Biopharma is currently not profitable relative to its asset base.
Staidson Beijing Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.46 | 1.10 | 4.34 |
| Quick Ratio | 2.22 | 0.98 | 4.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥181.43 Million | CN¥ 16.59 Million | CN¥ 695.12 Million |
Staidson Beijing Biopharma - Advanced Valuation Insights
This section examines the relationship between Staidson Beijing Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.79 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | -13.7% |
| Total Assets | CN¥1.15 Billion |
| Market Capitalization | $942.81 Million USD |
Valuation Analysis
Near Book Valuation: The market values Staidson Beijing Biopharma's assets close to their book value ( 0.82x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Staidson Beijing Biopharma's assets decreased by 13.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Staidson Beijing Biopharma (2007–2024)
The table below shows the annual total assets of Staidson Beijing Biopharma from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.15 Billion | -13.71% |
| 2023-12-31 | CN¥1.33 Billion | -20.19% |
| 2022-12-31 | CN¥1.67 Billion | -8.63% |
| 2021-12-31 | CN¥1.83 Billion | -1.57% |
| 2020-12-31 | CN¥1.86 Billion | -0.33% |
| 2019-12-31 | CN¥1.86 Billion | -32.82% |
| 2018-12-31 | CN¥2.77 Billion | +5.46% |
| 2017-12-31 | CN¥2.63 Billion | +11.82% |
| 2016-12-31 | CN¥2.35 Billion | +13.51% |
| 2015-12-31 | CN¥2.07 Billion | +14.29% |
| 2014-12-31 | CN¥1.81 Billion | +15.45% |
| 2013-12-31 | CN¥1.57 Billion | +9.53% |
| 2012-12-31 | CN¥1.43 Billion | +24.67% |
| 2011-12-31 | CN¥1.15 Billion | +333.93% |
| 2010-12-31 | CN¥264.88 Million | +78.07% |
| 2009-12-31 | CN¥148.75 Million | +61.57% |
| 2008-12-31 | CN¥92.07 Million | +11.98% |
| 2007-12-31 | CN¥82.22 Million | -- |